Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 13/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 12/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381663 | 0.93 | CDK9 (0.37) | FFAR4CDK9CCNT1PDE5AHDAC1 | |
| SCHEMBL11939277 | 0.91 | CDK9 (0.33) | FFAR4CDK9CCNT1PDE5AHDAC1 | |
| SCHEMBL11939367 | 0.90 | CDK9 (0.35) | CDK9CCNT1PDE5AHDAC1HDAC6 | |
| SCHEMBL15381760 | 0.89 | CDK9 (0.35) | FFAR4CDK9CCNT1PDE5AHDAC1 | |
| SCHEMBL11933388 | 0.89 | CDK9 (0.38) | CDK9CCNT1PDE5AHDAC1HDAC6 | |
| SCHEMBL11939185 | 0.88 | PDE5A (0.37) | CDK9CCNT1PTGS2PTGS1PDE5A | |
| SCHEMBL11938852 | 0.86 | CDK9 (0.34) | FFAR4CDK9CCNT1PTGS2PTGS1 | |
| SCHEMBL11939278 | 0.86 | CDK9 (0.34) | FFAR4CDK9CCNT1PDE5AHDAC1 | |
| SCHEMBL11939257 | 0.83 | FFAR4 (0.35) | FFAR4CDK9CCNT1ACACB | |
| SCHEMBL11933389 | 0.83 | CDK9 (0.37) | CDK9CCNT1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
| WO-2011033937-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | FFAR4 1038/4885CDK9 575/4885CCNT1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.